Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PHLPP1
REST API REST API
Homo sapiens
PHLPP1 is differentially expressed in 255 experiments: 129 organism parts: amygdala, spinal cord, ... (127 more);, 136 disease states: normal, glioblastoma, ... (134 more);, 84 cell types 378 cell lines 36 compound treatments and 61 other conditions.
Synonyms PHLPP, PLEKHE1, KIAA0606, SCOP
Orthologs PHLPP1 (Danio rerio)   PHLPP1 (Gallus gallus)   Phlpp1 (Mus musculus)   CYR1 (Saccharomyces cerevisiae)   Phlpp1 (Rattus norvegicus)   Phlpp (Drosophila melanogaster)   phlpp1 (Xenopus laevis)   PHLPP1 (Bos taurus)   PHLPP1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, apoptosis, cytoplasm, membrane, metal ion binding, protein serine/threonine phosphatase activity, fibroblast growth factor receptor signaling pathway, nucleus, hydrolase activity, circadian rhythm, catalytic activity, nerve growth factor receptor signaling pathway, phosphatidylinositol-mediated signaling
InterPro Term Leu-rich_rpt_typical-subtyp, Pleckstrin_homology, Leu-rich_rpt, PP2C-like
UniProt Accession O60346
Search EB-eye ENSG00000081913
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
A549
2
E-GEOD-6013, E-GEOD-3202
BT474
2
E-MEXP-440, E-MTAB-62
HCC1954
2
E-GEOD-29119, E-MTAB-37
HCC2157
2
E-MTAB-37, E-MTAB-62
HL-60
2
E-GEOD-5258, E-MTAB-37
372 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-MEXP-120, E-GEOD-13909, E-GEOD-20677, ... (47 experiments)

Factor Value U/D Experiments
mesenchymal stem cell
2
E-GEOD-2248, E-GEOD-9894
2
E-TABM-130, E-TABM-145
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
memory B cell
1
2
E-GEOD-17186, E-MEXP-2360, E-TABM-702
normal
1
E-GEOD-6883
78 more value(s).


Disease state

studied in E-GEOD-6872, E-GEOD-22529, E-GEOD-2508, E-GEOD-15960, E-GEOD-2466, ... (47 experiments)

Factor Value U/D Experiments
glioblastoma
1
3
E-GEOD-4290, E-MTAB-62, E-GEOD-4412, E-MEXP-567
obesity
2
E-MTAB-62, E-GEOD-2508
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
acute lymphoblastic leukemia
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-96
acute promyelocytic leukemia
1
2
E-MTAB-62, E-GEOD-96, E-GEOD-995
melanoma
1
E-MTAB-62
130 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-15205, E-GEOD-1417, E-TABM-782, E-GEOD-5099, ... (24 experiments)

Factor Value U/D Experiments
none
2
5
E-MEXP-1958, E-GEOD-412, E-GEOD-1417, E-GEOD-4600, E-TABM-782, ... (7 experiments)
glutamine
2
E-MEXP-941, E-MEXP-1335
anti-CD3 antibody (clone:OKT3)
1
E-MEXP-1601
sapphyrin PCI-2052
1
E-GEOD-6400
interferon-gamma + lipopolysaccharide
1
E-GEOD-5099
Cxcl12
1
E-GEOD-7307
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-19246, E-GEOD-21589, ... (6 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MEXP-1482, E-GEOD-20847, E-MEXP-563

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-MEXP-1235, E-GEOD-20115, ... (7 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-2657, E-GEOD-12773, E-TABM-127, ... (9 experiments)

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-2466, E-MEXP-1956, E-GEOD-1926, ... (26 experiments)

Infection
studied in E-GEOD-12254, E-GEOD-360

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22152, E-GEOD-21750, E-GEOD-1657, E-GEOD-4600 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-2466, E-GEOD-7540, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-GEOD-19246, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561

Processing time: 0.366 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM